P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS

Detalles Bibliográficos
Autores principales: Harrison, Claire, Patriarca, Andrea, Gupta, Vikas, Palandri, Francesca, Devos, Timothy, Rampal, Raajit K, Talpaz, Moshe, Vannucchi, Alessandro, Kuykendall, Andrew, Kiladjian, Jean-Jacques, Verstovsek, Srdan, Mesa, Ruben, Colak, Gozde, Dutta, Soumik, Klein, Sandra, Cui, Jie, Chang, Tzuu-Wang, Mascarenhas, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431464/
http://dx.doi.org/10.1097/01.HS9.0000971004.26914.cb
Descripción
Sumario:

Ejemplares similares